繁體
简体中文
繁體中文

Cytek BioSciences CTKB

等待開盤 09-11 09:30:00 美东时间

3.74

-0.190

-4.83%

华盛通華盛通
立即下載
  • 最 高3.995
  • 今 開3.93
  • 成交量 102.32万股
  • 最 低 3.72
  • 昨 收 3.93
  • 總市值 4.75亿
  • 52周最高 7.63
  • 市盈率 --
  • 換手率 0.81%
  • 52周最低 2.37
  • 委 比 -19.65%
  • 總股本 1.27亿
  • 歷史最高 28.70
  • 量 比 1.17
  • 振 幅 7.00%
  • 歷史最低 2.37
  • 每 手 1
  • 風險率 1.24%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

    Cytek Biosciences, a leader in spectral flow cytometry, will showcase its advanced solutions at the ESCCA 2025 Conference in Montpellier, France, and ICCS 2025 in Philadelphia. The company's Full Spectrum Profiling™ (FSP®) technology has revolutionized cell biology and diagnostics, enabling high-parameter analysis with reduced reagent use and streamlined workflows. At ESCCA, Joseph Lownik, MD, PhD, will present a workshop on integrating spectral ...

    09-10 21:00

  • 昆仑资本荣获「年度最佳CVC科技投资机构」等九项荣誉

    (来源:昆仑万维(维权))   昆仑资本由昆仑万维创始人周亚辉先生于2015年创立,专注于科技创新型企业投资,当前已在量子计算、可控核聚变、脑机接口、生物基因...

    09-03 18:54

  • Cytek Biosciences to Participate in Upcoming Investor Conferences

    Cytek Biosciences, Inc. announced its participation in several investor conferences, including the UBS Precision Medicine Summit in Dana Point, CA, featuring a panel discussion on August 14; the Wells Fargo Healthcare Conference in Boston, MA, with investor meetings on September 4; and the Morgan Stanley Global Healthcare Conference in New York, NY, hosting a fireside chat on September 10. The company, known for its advanced cell analysis solutio...

    08-12 20:05

  • Cytek Biosciences Earnings Call Reveals Mixed Outlook

    Cytek Biosciences, Inc. (($CTKB)) has held its Q2 earnings call. Read on for th...

    08-08 09:51

  • Cytek Biosciences Narrows FY2025 Sales Guidance from $196.000M-$210.000M to $196.000M-$205.000M vs $198.301M Est

    Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.000 million vs $198.301 million estimate.

    08-07 04:28

  • Earnings Scheduled For August 6, 2025

    Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...

    08-06 16:33

  • Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025

    Cytek Biosciences announced it will release its Q2 2025 financial results after market close on August 6, 2025. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments, and outlook. A live audio webcast will be available on the company’s Investor Relations website. Cytek Biosciences is a leading provider of advanced cell analysis solutions, leveraging its patented Full Spectrum Profi...

    07-23 20:05

  • 美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价!

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通:维持Cogent Biosciences(COGT)"超配"评级,目标价从21美元升至25美元</p> <p>• Chardan Capital:维持Taysha Gene Therapies(TSHA)"买入"

    05-30 09:09

  • Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

    Cytek Biosciences, Inc. debuted the Cytek Aurora™ Evo system, a high-performance flow cytometer that enhances its predecessor's reliability and reproducibility with added high-throughput and automation features. The system leverages Cytek’s Full Spectrum Profiling™ technology, improving sample throughput, automating maintenance, and enabling detection of small particles like extracellular vesicles. Designed for modern research demands, the Cytek ...

    05-29 21:00

  • 美股大行评级 | 拼多多遭多家大行下调评级!Redburn Atlantic首予博通"买入"评级

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim:维持AnaptysBio(ANAB)"买入"评级,目标价从54美元升至90美元</p> <p>• Canaccord Genuity:维持Bridger Aerospace Gr(BAER)"买入"评

    05-29 09:53